Prediabetes

  1. What is Prediabetes?
  2. Diagnostic Criteria
  3. Insulin Resistance vs. Beta-Cell Dysfunction
  4. Risk Factors
  5. Lifestyle Intervention — The Diabetes Prevention Program
  6. Metformin vs. Lifestyle Intervention
  7. Monitoring and Screening Intervals
  8. Nutrition and Exercise Strategies
  9. Key Research Papers
  10. Connections

What is Prediabetes?

Blood glucose is above normal but below the threshold for diabetes. ADA 2024 criteria: fasting glucose 100–125 mg/dL (impaired fasting glucose), or HbA1c 5.7–6.4%, or 2-hour OGTT glucose 140–199 mg/dL. An estimated 96 million U.S. adults have prediabetes; 80% are undiagnosed (CDC 2022). Without intervention, approximately 37% progress to type 2 diabetes within 4 years.

Back to Table of Contents

Diagnostic Criteria

Three equivalent screening tests: (1) Fasting plasma glucose (FPG) 100–125 mg/dL — must fast ≥8 hours. (2) HbA1c 5.7–6.4% — reflects 2–3 month average; affected by hemoglobinopathies, iron deficiency, kidney disease. (3) Oral glucose tolerance test (OGTT) 2-hour value 140–199 mg/dL after 75 g glucose load — most sensitive, catches isolated postprandial dysglycemia. Any single abnormal result on a high-risk individual warrants a repeat test to confirm.

Back to Table of Contents

Insulin Resistance vs. Beta-Cell Dysfunction

Prediabetes arises from two overlapping defects. Insulin resistance: skeletal muscle, liver, and adipose tissue respond less effectively to insulin — driven by visceral fat, physical inactivity, inflammation, and lipotoxicity. Beta-cell dysfunction: pancreatic beta cells fail to compensate with adequate insulin secretion — early impairment of first-phase insulin release is characteristic. IFG (elevated fasting glucose) reflects primarily hepatic insulin resistance and impaired fasting insulin suppression. IGT (elevated post-OGTT glucose) reflects more peripheral (muscle) insulin resistance and beta-cell exhaustion. Both defects coexist in most people with prediabetes.

Back to Table of Contents

Risk Factors

Age ≥45, BMI ≥25 kg/m² (≥23 in Asian Americans), family history of type 2 diabetes (first-degree), gestational diabetes history, PCOS, physical inactivity, hypertension (≥140/90 mmHg), dyslipidemia (HDL <35 mg/dL or triglycerides >250 mg/dL), history of cardiovascular disease, acanthosis nigricans, sleep apnea, antipsychotic medication use, and certain ethnic groups (Hispanic/Latino, Black, Asian American, Native American — higher incidence at lower BMI).

Back to Table of Contents

Lifestyle Intervention — The Diabetes Prevention Program

The landmark DPP RCT (NEJM 2002, n=3,234) showed intensive lifestyle intervention reduced type 2 diabetes incidence by 58% over 2.8 years versus placebo. Goals: ≥7% body weight loss and ≥150 min/week of moderate activity. Metformin arm reduced risk by 31%. The DPP Outcomes Study (DPPOS) followed participants for 15 years: lifestyle benefit persisted, with cumulative incidence 27% lower than placebo at 10 years. CDC-recognized National DPP is now covered by Medicare for beneficiaries with prediabetes.

Back to Table of Contents

Metformin vs. Lifestyle Intervention

Metformin 850 mg twice daily is recommended by the ADA as adjunct to lifestyle for high-risk individuals: BMI ≥35, age <60, prior gestational diabetes, or HbA1c >6%. Head-to-head in DPP: lifestyle outperformed metformin overall, but metformin was more effective in younger patients and those with higher BMI. Metformin is not FDA-approved for prediabetes prevention (used off-label); it costs ~$4/month generic. Lifestyle is first-line because it also reduces cardiovascular risk factors beyond glucose. Both interventions are synergistic; neither cures the underlying defect.

Back to Table of Contents

Monitoring and Screening Intervals

All adults ≥35 should be screened regardless of risk. ADA recommends retesting every 1–3 years for those with prediabetes (annual if close to the diabetes threshold). Monitor: fasting glucose, HbA1c, lipid panel, blood pressure, kidney function (eGFR, urine albumin-to-creatinine ratio). Regression to normoglycemia occurs in about 40% of people with prediabetes over 4 years and is associated with weight loss, younger age, and lower baseline glucose.

Back to Table of Contents

Nutrition and Exercise Strategies

Dietary approaches: Mediterranean diet, DASH, and low-carbohydrate diets all show benefit in reducing HbA1c and fasting glucose. Key principles: reduce refined carbohydrates and sugar-sweetened beverages, increase dietary fiber (≥25 g/day), prefer whole grains, legumes, and non-starchy vegetables. Exercise: aerobic exercise (brisk walking, cycling) improves peripheral insulin sensitivity; resistance training independently lowers HbA1c; combination is superior. Structured programs achieving ≥150 min/week of moderate activity are equivalent to pharmaceutical interventions for many patients.

Back to Table of Contents

Key Research Papers

  1. Knowler WC et al. (DPP), 2002 — PMID: 11832527 — Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
  2. Diabetes Prevention Program Research Group, 2009 — PMID: 19878986 — 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-1686.
  3. American Diabetes Association. Standards of Care 2024. Diabetes Care. 2024;47(Suppl 1).
  4. Tabak AG et al., 2012 — PMID: 22683128 — Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279-2290.
  5. Perreault L et al. — Regression from prediabetes to normal glucose regulation. Lancet. 2012;379(9833):2243-2251.
  6. Gerstein HC et al., 2007 — PMID: 17259469 — Annual incidence and relative risk of diabetes in various categories of dysglycemia. Diabetes Care. 2007;30(2):442-447.
  7. Tuomilehto J et al. (Finnish DPS), 2001 — PMID: 11333990 — Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350.
  8. Haw JS et al., 2017 — PMID: 29059261 — Long-term sustainability of diabetes prevention approaches. JAMA Intern Med. 2017;177(12):1808-1817.
  9. Lily M, Godwin M. — Treating prediabetes with metformin. Can Fam Physician. 2009.
  10. Salas-Salvado J et al. (PREDIMED), 2011 — PMID: 20929998 — Reduction in the incidence of type 2 diabetes with the Mediterranean diet. Diabetes Care. 2011;34(1):14-19.
  11. Colberg SR et al., 2010 — PMID: 21115758 — Exercise and type 2 diabetes. Diabetes Care. 2010;33(12):e147-e167.
  12. Blonde L et al., 2022 — PMID: 35674304 — American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan.

PubMed Topic Searches

Connections